You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 26, 2026

Bulk Pharmaceutical API Sources for METHYLPREDNISOLONE


✉ Email this page to a colleague

« Back to Dashboard


Bulk Pharmaceutical API Sources for METHYLPREDNISOLONE

Vendor Vendor Homepage Vendor Sku API Url
Sigma-Aldrich ⤷  Start Trial M0639_SIGMA ⤷  Start Trial
NovoSeek ⤷  Start Trial 6741 ⤷  Start Trial
TCI (Tokyo Chemical Industry) ⤷  Start Trial M1665 ⤷  Start Trial
MolPort ⤷  Start Trial MolPort-002-528-554 ⤷  Start Trial
NIH Clinical Collection ⤷  Start Trial SAM002589984 ⤷  Start Trial
>Vendor >Vendor Homepage >Vendor Sku >API Url

Methylprednisolone Bulk API Sources

Last updated: February 20, 2026

Who are the primary suppliers of methylprednisolone API?

Multiple regions produce methylprednisolone API, with leading suppliers based in India, China, and Europe. These manufacturers provide various grades, including pharmaceutical-grade and research bulk quantities.

What are the main sources of methylprednisolone API?

Region Notable Manufacturers Production Capacity & Certifications Market Focus
India Sun Pharmaceutical Industries, Natco Pharma, Aurobindo Pharma Large-scale production, WHO-GMP, ISO 9001, stringent regulatory compliance Domestic and export markets, especially US, Europe, and South America
China Shanghai Fosun Pharmaceutical, Bayer China, Zhejiang Huahai Pharmaceutical Extensive manufacturing capacity, GMP, ISO standards, competitive pricing Global supply, including emerging markets
Europe Recipharm, Sandoz (Novartis), STADA Arzneimittel AG High regulatory standards, EMA-approved facilities, quality control European markets, North America

What are key supplier characteristics?

  • Quality standards: Suppliers operate under Good Manufacturing Practice (GMP). Many hold certifications from the World Health Organization (WHO), the U.S. Food and Drug Administration (FDA), and the European Medicines Agency (EMA).
  • Pricing: Chinese and Indian suppliers tend to offer more competitive pricing, with batch costs often 20-40% lower than European counterparts.
  • Lead times: Indian suppliers can deliver API within 4-8 weeks for bulk orders. Chinese suppliers provide similar timelines, but export logistics can affect delivery.
  • Regulatory status: European suppliers often maintain higher regulatory documentation standards, aligning with EMA requirements. Indian and Chinese suppliers frequently seek Food and Drug Administration (FDA) inspection authorization for export to the US.

How does API sourcing affect the pharmaceutical supply chain?

  • Cost impact: Indian and Chinese APIs reduce manufacturing costs and influence global market pricing.
  • Quality control: European suppliers maintain tighter quality assurance, aligning with stricter regulatory environments.
  • Supply stability: Diversification across regions reduces dependency on single-source suppliers, decreasing risks related to geopolitical or trade disruptions.

How are regulatory variances managed?

  • Certifications: Suppliers with ISO 9001, GMP, and WHO certifications are preferred.
  • Audits: Contract manufacturing organizations (CMOs) often perform audits to verify quality standards.
  • Documentation: Certificates of analysis (CoA), batch records, and stability data are critical for compliance, particularly for regulatory submissions in developed markets.

What considerations influence API sourcing decisions?

  • Price versus quality: Lower-cost APIs from China and India often involve variable documentation. Buyers balance cost savings against regulatory risk.
  • Supply chain reliability: Long-term agreements with established suppliers mitigate delays.
  • Regulatory approvals: Suppliers with established FDA or EMA approvals streamline regulatory pathways and reduce approval timeframes.

Summary

Major countries producing methylprednisolone API include India, China, and European nations. Indian and Chinese manufacturers offer cost advantages but may have variable regulatory documentation quality. European producers prioritize compliance and documentation, often at higher costs. Selection depends on regulatory requirements, cost constraints, and supply chain stability.

Key Takeaways

  • India, China, and Europe are primary methylprednisolone API sources.
  • Indian and Chinese manufacturers deliver more cost-effective solutions with variable documentation quality.
  • European sources emphasize regulatory compliance, suited for markets with strict standards.
  • Supply chain continuity depends on supplier certification, production capacity, and logistical factors.
  • Buyers must evaluate quality, cost, regulatory status, and supply stability when sourcing API.

FAQs

1. Which region offers the most cost-effective methylprednisolone API?
India and China typically provide the lowest prices, often 20-40% less than European suppliers.

2. What are the regulatory considerations in sourcing from China?
Chinese suppliers may have variable documentation standards; selecting those with GMP, ISO, or FDA inspection approvals minimizes compliance risks.

3. Do European suppliers offer better quality assurance?
Yes. European manufacturers usually operate under higher regulatory standards, providing comprehensive documentation and quality control.

4. How can supply chain disruptions be mitigated?
Diversify suppliers across regions, establish long-term agreements, and verify certification statuses to ensure stable supply.

5. What documentation should be requested from API suppliers?
Certificates of analysis, batch production records, stability data, and regulatory compliance certificates are essential for quality assurance.


References

  1. U.S. Food and Drug Administration. (2021). Drug Master Files: Injectable and Oral Steroids. Retrieved from https://www.fda.gov
  2. World Health Organization. (2020). WHO Good Manufacturing Practices. Retrieved from https://www.who.int
  3. European Medicines Agency. (2022). Manufacturing Authorizations. Retrieved from https://www.ema.europa.eu
  4. Indian Pharmaceutical Alliance. (2021). API Industry Overview. Retrieved from https://www.ipapharma.org
  5. China Pharmacopoeia Commission. (2020). Pharmaceutical Standards. Retrieved from https://www.chinapharm.com

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.